Skip to content
Popular Searches
  • # Cancer
  • # FDA
  • # Alzheimer's
  • # Hoffmann-La Roche
  • # FDA Approval
  • # DNA
  • linkedin
  • facebook
  • instagram
  • twitter
  • youtube
Home BiotechReality – Covering Industry, Business, and Academia

Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.

  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
Trending

Trending

Recurring COVID-19 vaccines produce antibodies that fight off other viruses and their variations.

22 May 2024

Atomic-level view in native mitochondria obtained using in situ microscopy

9 June 2024

Roche’s Supplemental Biologics License Application of Gazyva/Gazyvaro (Obinutuzumab) for The Treatment of Lupus Nephritis Accepted by U.S. FDA

6 March 2025

Light-powered yeast; an opening to the insights of evolution, cellular ageing, and biofuels

13 January 2024

AbbVie’s Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Migraine Study

19 June 2025

HPLC – High-Performance Liquid Chromatography

2 September 2023

Discovery of new T cells and genes related to immune disorders

6 July 2024

Malaria – Parasite, Vector and the ongoing battle against a silent killer

20 June 2023

Researchers Find Possible Connections Between Skin Ageing and Microbiome

15 January 2024

Epstein-Barr virus’s new approach for causing diseases

29 May 2024

Cancer can be blocked by Statin therapy, which can block the inflammatory protein

5 June 2024

Understanding Prophase: Roles in Mitosis and Meiosis (Prophase I & II)

2 June 2025

CREST trial

Pfizer released Phase 3 CREST trial results shows reduction of disease-related events in high-risk non-muscle invasive bladder cancer
Clinical Trials Healthcare & Pharmaceuticals News

Pfizer released Phase 3 CREST trial results shows reduction of disease-related events in high-risk non-muscle invasive bladder cancer

Ajmal Aseem 29 April 2025

In more than three decades, the first possible therapy breakthrough for BCG-naïve, high-risk non-muscle invasive bladder cancer has been the combination of BCG and sasanlimab, a subcutaneously administered PD-1 inhibitor.

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • Cell Biology
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Life Sciences
  • Machine Learning
  • Medical Devices
  • Mental Health
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs
Market Analysis
Publish on BiotechReality

  • Cytiva Hiring a Quality Control Technician in Cardiff, United Kingdom
  • PhD Position in Dialysis Therapy – University of Twente, Netherlands
  • Eli Lilly and Company Hiring a Analytical Technical Steward-Peptides in Hyderabad, India – June, 2025
  • ICON Hiring a Clinical Data Programming Lead in Chennai, India
  • PhD Position in Food Biotechnology – University of Reading, United Kingdom
SciRealityPress BiotechReality

A SciRealityPress Associate

DMCA.com Protection Status

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2025
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinuePrivacy policy